Pamedic Focuses on Ongoing Innovation in the Radioisotope Pharmaceutical Field

Pamedic Holdings has been dedicated to the research and innovation of isotope core drugs, continuously monitoring and supporting innovative developments within the industry. Recently, innovative news in the isotope field has garnered strong attention in the nuclear medicine sector.

Innovations in the Isotope Pharmaceutical Field

1、[ARTBIO: Radiopharmaceutical Company Secures Over $90 Million in Series A Funding]

ARTBIO announced the successful completion of an oversubscribed Series A funding round, raising over $90 million, with lead investors F-Prime Capital and Omega Funds significantly participating. This reflects investors' strong interest in novel alpha-radioisotope targeted therapy (ARTs).

2、[Ractigen Therapeutics RAG-01: RNA Activation Breakthrough]

Ractigen Therapeutics RAG-01 from Meirui Health became the world's second saRNA drug to enter clinical stages, marking China's first achievement in this milestone for saRNA drugs. This breakthrough highlights the potential of RNA activation technology in treating various diseases, especially its innovative application in cancer treatment.

3、[Lepu Biopharma's MRG003: Breakthrough in NPC Treatment]

Lepu Biopharma's independently developed EGFR-targeted ADC product, MRG003, has been granted FDA fast-track designation, providing new hope for the treatment of advanced nasopharyngeal carcinoma (NPC). This accomplishment not only recognizes Lepu Biopharma's innovation capabilities but also underscores the promising future of radioisotope pharmaceuticals in cancer treatment.

4、[CARsgen's CT071: Advancements in CAR-T Cell Therapy]

CARsgen's CT071 received FDA IND approval, becoming a CAR-T cell candidate for relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia. This demonstrates the enormous potential of CAR-T technology in the treatment of hematologic malignancies and injects new vitality into radioisotope medicine.

5、[China National Nuclear Corporation Achieves Independent Development of Kilogram-Level 99% Enriched Molybdenum-100 Isotope, Ensuring Autonomous Supply in China]

China National Nuclear Corporation Chemistry Institute/Company announced a significant breakthrough, achieving independent development of kilogram-level 99% enriched molybdenum-100 isotope in China for the first time. This milestone ends China's long-term reliance on imported molybdenum isotopes, showcasing the country's world-leading position in high-enriched stable isotope research.

Pamedic Holdings keenly observes this as a clear signal of renewed high attention in the isotope pharmaceutical field. We will continue to leverage our professional expertise, dedicating ourselves to driving innovation and development in the isotope pharmaceutical field. By consistently monitoring market demands, we strive to identify and promote more forward-thinking innovative opportunities to meet patient and market needs.

Pamedic Holdings' Future Outlook

Pamedic Holdings is a company focused on the technical research and development of medical isotope pharmaceuticals, established in the Hetaoyuan area of Futian District, Shenzhen. The company was jointly initiated by Hong Kong C Cheng Holdings Limited, MWA.T Industrial Consulting Company, and UK-based PMHL Company, with the aim of advancing innovation in the field of nuclear medicine. Its core technical team comprises top talents in the isotope field from both China and the UK.

As a participant in the isotope pharmaceutical field, Pamedic Holdings will continue to closely monitor industry innovation trends and strive to drive the development of radiopharmaceuticals. We look forward to collaborating with global partners to explore cutting-edge technologies and provide safer and more effective treatment options for patients.

If you are interested in our research direction or collaboration opportunities, please feel free to contact us at any time. Let's work together to advance the development of the isotope pharmaceutical field."